Evidence map›Paper›PMID 39615426›Full record

ReviewCurrent opinion in chemical biology2025

Discovering microbiota functions via chemical probe incorporation for targeted sequencing.

Natalie Falco, Matthew E Griffin

Abstract readReview
In one paragraph

Review in Current opinion in chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Natalie FalcoDepartment of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA 92697, USA.
Matthew E GriffinDepartment of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA 92697, USA; Department of Molecular Biology & Biochemistry, University of California, Irvine, Irvine, CA 92697, USA; Department of Chemistry, University of California, Irvine, Irvine, CA 92697, USA. Electronic address: griffin@uci.edu.

Funding

Augmenting cancer checkpoint immunotherapies via microbially-derived metabolitesK22CA272915 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI GRIFFIN, MATTHEW EVERETT · 2023 to 2025
$483k
Chemoproteomic discovery of secreted microbial enzymes for engineered probioticsF31AI178923 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FALCO, NATALIE · 2024 to 2025
$92k
NCI NIH HHS K22 CA272915NIAID NIH HHS F31 AI178923
6 · The paper itself

Abstract

Our microbiota plays crucial roles in immune development and homeostasis and has been implicated in virtually all major diseases of the 21st century. Nevertheless, our understanding of the exact microbial functions that underlie these correlations remains extremely limited, due in large part to the difficulty of profiling cellular activities within non-model organisms and complex communities. Over the past decade, new flow cytometric approaches have been developed to distinguish specific microbial populations based on their interactions with metabolite analogs, modified biomolecules, and reactive compounds. By selecting and separating active microbes via fluorescence-activated cell sorting, PRobe INcorporation for Targeted sequencing (PRINT-seq) has inspired innovative approaches to identify and characterize functional members of our microbiota. Here, we provide a broad overview of this evolving technology and summarize how this method has been recently employed as a diagnostic fingerprint for diverse microbial activities.

Indexed as

BacteriaMicrobiotaMolecular ProbesAnimalsFlow CytometryHumansMolecular ProbesBioorthogonal chemistryClick chemistryFlow cytometryFluorescence-activated cell sortingMetabolic labelingMicrobiotaNext-generation sequencingRaman microspectroscopyStable isotope probing

Identifiers

PMID39615426
PMCPMC11799120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.